On the Delta Plus Variant of SARS-CoV-2



Abstract Views
898

Downloads
172

Citations

Share

##plugins.themes.bootstrap3.article.sidebar##

Submitted Nov 6, 2021
Published Dec 24, 2021
10.24018/ejmed.2021.3.6.1134

Abstract viewed = 898 times

Table of Contents

##plugins.themes.bootstrap3.article.main##

The unprecedented consequences brought by the COVID pandemic are still going on, the virus hasn’t been tamed yet. It is evolving through mutations to consistently being a risk to public health. Recently, the Delta variant has been declared as the variant of concern by the World Health Organization (WHO). In this article, a subvariant of Delta known as Delta Plus has been presented to provide a relevant foundation for future research works. The evolution, pathogenesis, associated symptoms, suggested prevention and treatments, vaccine efficacy, and current trends of transmission of Delta Plus variant of SARS-CoV-2 are reviewed and discussed.

Keywords: COVID-19, delta, delta plus, mutation, epidemiology, management, vaccine efficacy

Downloads

Download data is not yet available.

References

  1. Chowdhury S, Bappy MH, Chowdhury S, Chowdhury MS, Chowdhury NS. Current Review of Delta Variant of SARS-CoV-2. European Journal of Medical and Health Sciences. 2021; 3(6): 23-9.
    DOI  |   Google Scholar
  2. Tracking SARS-CoV-2 variants [Internet]. [cited 2021 Dec 2]. Available from: https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/
     Google Scholar
  3. GISAID - hCov19 Variants [Internet]. [cited 2021 Dec 2]. Available from: https://www.gisaid.org/hcov19-variants/
     Google Scholar
  4. CDC. What you need to know about variants [Internet]. 2021 [cited 2021 Dec 2]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/variants/variant.html
     Google Scholar
  5. Roy B, Roy H. The Delta Plus variant of COVID-19: Will it be the worst nightmare in the SARS-CoV-2 pandemic? Journal of Biomedical Sciences. 2021; 8(1).
    DOI  |   Google Scholar
  6. Kyriakidis NC, López-Cortés A, González EV, Grimaldos AB, Prado EO. SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. NPJ Vaccines. 2021; 6(1).
    DOI  |   Google Scholar
  7. Public Health England. SARS-CoV-2 variants of concern and variants under investigation in England. technical briefing 12. 2021.
     Google Scholar
  8. Alexander A. A potentially faster-spreading Delta variant, AY.4.2, has been spotted in 8 states [Internet]. CBS News. 2021 [cited 2021 Dec 2]. Available from: https://www.cbsnews.com/news/covid-delta-plus-variant-ay-4-2-states/
     Google Scholar
  9. Wikipedia contributors. SARS-CoV-2 Delta variant [Internet]. Wikipedia, The Free Encyclopedia. 2021 [cited 2021 Dec 2]. Available from: https://en.wikipedia.org/w/index.php?title=SARS-CoV-2_Delta_variant&oldid=1058079794
     Google Scholar
  10. Becerra A, Muñoz-Velasco I, Aguilar-Cámara A, Cottom-Salas W, Cruz-González A, Vázquez-Salazar A, et al. Two Short Low Complexity Regions (LCRs) are Hallmark Sequences of the Delta SARS-CoV-2 Variant Spike Protein. 2021.
    DOI  |   Google Scholar
  11. Kannan SR, Spratt AN, Cohen AR, Naqvi SH, Chand HS, Quinn TP, et al. Evolutionary analysis of the delta and Delta Plus variants of the SARS-CoV-2 viruses. Journal of Autoimmunity. 2021; 102715.
    DOI  |   Google Scholar
  12. CDC. COVID Data Tracker. [Internet]. 2020 [cited 2021 Dec 2]. Available from: https://covid.cdc.gov/covid-data-tracker/
     Google Scholar
  13. CDC. Delta variant: What we know about the science. [Internet]. 2021 [cited 2021 Dec 2]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/variants/delta-variant.html
     Google Scholar
  14. Burn-Murdoch J. New Delta descendant may be more infectious than its ancestor. Financial Times [Internet]. 2021 [cited 2021 Dec 2]; Available from: https://www.ft.com/content/f1ec9d5d-9e02-4cc4-95e7-1dcbb1844d43
     Google Scholar
  15. Chowdhury S, Bappy MH, Chowdhury S, Chowdhury MS, Chowdhury NS. COVID-19 induced cardiovascular complications and recent therapeutic advances. European Journal of Medical and Health Sciences. 2021; 3(6): 17-22.
    DOI  |   Google Scholar
  16. Ong SWX, Chiew CJ, Ang LW, Mak TM, Cui L, Toh MPH, et al. Clinical and Virological Features of SARS-CoV-2 Variants of Concern: A Retrospective Cohort Study Comparing B. Clinical Infectious Disease. 2021; 1: 1.
     Google Scholar
  17. Fisman D, Tuite A. Progressive Increase in Virulence of Novel SARS-CoV-2 Variants in Ontario. Canada; 2021.
    DOI  |   Google Scholar
  18. CDC. Symptoms of COVID-19. [Internet]. 2021 [cited 2021 Dec 2]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html
     Google Scholar
  19. Miller K. What is the Delta Plus variant? Here’s what experts know about it so far. [Internet]. 2021 [cited 2021 Dec 2]. Available from: https://www.prevention.com/health/a37221697/what-is-delta-plus-variant-covid-19/
     Google Scholar
  20. Treatments for COVID-19. [Internet]. 2021 [cited 2021 Dec 2]. Available from: https://www.health.harvard.edu/diseases-and-conditions/treatments-for-covid-19
     Google Scholar
  21. Information on COVID-19 treatment, prevention and research. [Internet]. [cited 2021 Dec 2]. Available from: https://www.covid19treatmentguidelines.nih.gov/
     Google Scholar
  22. Planas D, Veyer D, Baidaliuk A, Staropoli I, Guivel-Benhassine F, Rajah MM, et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature. 2021.
    DOI  |   Google Scholar
  23. Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of Covid-19 vaccines against the B. New England Journal of Medicine. 2021; 1: 617.
    DOI  |   Google Scholar
  24. Moline HL, Whitaker M, Deng L, Rhodes JC, Milucky J, Pham H, et al. Effectiveness of COVID-19 vaccines in preventing hospitalization among adults aged ≥65 years — COVID-NET, 13 states, February–April 2021. MMWR Morb Mortal Wkly Rep. 2021;70(32):1088–93.
    DOI  |   Google Scholar
  25. Tenforde MW, Self WH, Naioti EA, Ginde AA, Douin DJ, Olson SM, Talbot HK, Casey JD, Mohr NM, Zepeski A, Gaglani M. Sustained effectiveness of Pfizer-BioNTech and Moderna vaccines against COVID-19 associated hospitalizations among adults—United States, March–July 2021. Morbidity and Mortality Weekly Report. 2021; 70(34): 1156.
    DOI  |   Google Scholar


Most read articles by the same author(s)